Applicant: Zhaoda Zhang et al. Attorney's Docket No.: 13498-010003 / MET-14

Serial No.: 10/786,791

Filed: February 25, 2004

Page : 2 of 15

#### Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

# Listing of Claims:

1.-10. (Cancelled).

- 11. (Currently amended) A method of making an MR imaging agent, said method comprising:
- a) reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having a C-terminal amine functional group and said N-terminal amine functional group;
- b) covalently attaching a linker moiety to the C-terminal amine functional group and to the N-terminal amine functional group to form a precursor MR imaging agent;
- c) converting the precursor MR imaging agent to the MR imaging agent; wherein converting the precursor MR imaging agent to the MR imaging agent comprises:
- (d) reacting the precursor MR imaging agent with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the precursor MR imaging agent, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties;
- (e) transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and
- (f) complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent;

Applicant: Zhaoda Zhang et al.

Serial No.: 10/786,791

Filed: February 25, 2004

Page : 3 of 15

# wherein the linker-subunit moiety is:

$$H_2N$$
  $NH_2$ 

The method of claim 8, wherein the precursor chelate moiety is selected from the group consisting of:

wherein LG is a leaving group selected from the group consisting of—OH, activated ester, halide, and anhydride, and wherein each R, independently, is an O or an O precursor selected from the group consisting of OH, -O-Me, O-Et, O-tBu, O-benzyl, and O-allyl, so that R, upon conversion to O, is capable of forming a carboxylate moiety with its adjacent carbonyl.

### 12. - 13. (Cancelled).

Applicant: Zhaoda Zhang et al.

Serial No.: 10/786,791


Filed : February 25, 2004

: 4 of 15 Page

(Currently amended) A method of making an MR imaging agent, said method 14. comprising:

- a) reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having a C-terminal amine functional group and said Nterminal amine functional group;
- b) covalently attaching a linker moiety to the C-terminal amine functional group and to the N-terminal amine functional group to form a precursor MR imaging agent;
- c) converting the precursor MR imaging agent to the MR imaging agent; wherein converting the precursor MR imaging agent to the MR imaging agent comprises:
- (d) reacting the precursor MR imaging agent with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the precursor MR imaging agent, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties;
- (e) transforming a plurality of the carboxylate precursor groups of the bound precursor chelate moiety to a plurality of carboxylate moieties, the carboxylate moieties capable of complexing a paramagnetic metal ion; and
- (f) complexing a paramagnetic metal ion to the plurality of carboxylate moieties to produce the MR imaging agent;

wherein the linker-subunit moiety is:



wherein the precursor chelate moiety is selected from the group consisting of:

Applicant: Zhaoda Zhang et al. Serial No.: 10/786,791

: February 25, 2004 Filed

: 5 of 15 Page

Applicant: Zhaoda Zhang et al. Attorney's Docket No.: 13498-010003 / MET-14

Serial No.: 10/786,791

Filed: February 25, 2004

Page : 6 of 15

### wherein:

# n is an integer from 1 to 4;

R is selected from the group consisting of a negative charge and a negative charge precursor capable of being transformed into a negative charge; and

X is a chemical leaving group selected from the group consisting of -Cl, -Br, -I, -MsO, -TsO, and -TfO; and

The method of claim 12 or 13, wherein the negative charge precursor is selected from the group consisting of -H, -Me, -Et, -t-Bu, -benzyl, and -allyl.

- 15. (Cancelled).
- 16. (Currently amended) <u>A method of making an MR imaging agent, said method comprising:</u>

Applicant: Zhaoda Zhang et al.

Serial No.: 10/786,791 Filed: February 25, 2004

Page : 7 of 15

a) reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having a C-terminal amine functional group and said N-terminal amine functional group;

- b) covalently attaching a linker moiety to the C-terminal amine functional group and to the N-terminal amine functional group to form a precursor MR imaging agent; and
  - c) converting the precursor MR imaging agent to the MR imaging agent;

wherein the linker-subunit moiety is:

wherein the linker moiety is covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties;

The method of claim 15, wherein the covalent conjugate is selected from the group consisting of

and

Applicant: Zhaoda Zhang et al.

Serial No.: 10/786,791 Filed: February 25, 2004

Page : 8 of 15


wherein n is an integer from 1 to 4;

LG is a leaving group selected from the group consisting of -OH, activated ester, halide, and anhydride; and

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5</sup> are independently selected from the group consisting of an acetate moiety, a –Me, -Et, or -t-Bu protected acetate moiety, an acetamide moiety, and an acetoxy moiety.

- 17. (Currently amended) <u>A method of making an MR imaging agent, said method comprising:</u>
- a) reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having a C-terminal amine functional group and said N-terminal amine functional group;
- b) covalently attaching a linker moiety to the C-terminal amine functional group and to the N-terminal amine functional group to form a precursor MR imaging agent; and
  - c) converting the precursor MR imaging agent to the MR imaging agent;

wherein the linker-subunit moiety is:



Applicant: Zhaoda Zhang et al.

Serial No.: 10/786,791 Filed: February 25, 2004

Page : 9 of 15

wherein the linker moiety is covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties;

The method of claim 15, wherein the covalent conjugate is selected from the group consisting of:

### wherein:

LG is a leaving group selected from the group consisting of -OH, activated ester, halide, and anhydride; and

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are selected from the group consisting of an acetate moiety, a –Me, -Et, or -t-Bu protected acetate moiety, an acetamide moiety, and an acetoxy moiety.

- 18. (Cancelled).
- 19. (Currently amended) A method of making an MR imaging agent, said method comprising:

Applicant: Zhaoda Zhang et al. Attorney's Docket No.: 13498-010003 / MET-14

Serial No.: 10/786,791


Filed: February 25, 2004

Page : 10 of 15

a) reacting a peptide having an N-terminal amine functional group with a linker-subunit moiety to form a modified peptide having a C-terminal amine functional group and said N-terminal amine functional group;

- b) covalently attaching a linker moiety to the C-terminal amine functional group and to the N-terminal amine functional group to form a precursor MR imaging agent; and
  - c) converting the precursor MR imaging agent to the MR imaging agent;

wherein the linker-subunit moiety is:



wherein the linker moiety is covalently conjugated to a precursor chelate moiety, the covalent conjugate comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties;

The method of claim 15, wherein the covalent conjugate is selected from the group consisting of:

Applicant: Zhaoda Zhang et al.

Serial No.: 10/786,791

Filed: February 25, 2004

Page : 11 of 15

wherein:

R is a -tBu group,

LG is a leaving group selected from the group consisting of –OH, activated ester, halide, and anhydride.

- 20. (Cancelled).
- 21. (Currently amended) The method of <u>claim 11 or 14</u>, <u>claim 8 or claim 20</u>, wherein the paramagnetic metal ion is selected from the group consisting of: Gd(III), Fe(III), Mn(II and III), Cr(III), Cu(II), Dy(III), Tb(III and IV), Ho(III), Er(III), Pr(III), Eu(II) and Eu(III).
- 22. (Original) The method of claim 21, wherein the paramagnetic metal ion is Gd(III).
- 23. 64. (Cancelled).

Applicant: Zhaoda Zhang et al.

Serial No.: 10/786,791

: February 25, 2004 Filed : 12 of 15

Page

(Currently amended) A method for altering the stability of a peptide, the peptide having 65. an N-terminal amine functional group, the method comprising:

a) reacting the peptide with a linker-subunit moiety to form a peptide having a C-terminal amine functional group, wherein the linker-subunit moiety is:

$$H_2N$$
  $NH_2$ 

b) covalently attaching a linker moiety to the peptide's C-terminal amine functional group and N-terminal amine functional group to form a modified peptide;

- c) reacting the modified peptide with a precursor chelate moiety to form a covalent bond between the precursor chelate moiety and the linker moiety of the modified peptide, the precursor chelate moiety comprising a plurality of carboxylate precursor groups, the carboxylate precursor groups capable of being transformed into carboxylate moieties; and
- d) assaying the stability of the modified peptide and optionally comparing the stability of said modified peptide to the stability of said unmodified peptide;

The method of claim 59 or claim 60, wherein the stability is assayed using a rat liver homogenate assay.

(Cancelled). 66. – 77.